We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.61 | 1.95% | 31.92 | 31.85 | 32.00 | 31.95 | 31.53 | 31.53 | 1,828,049 | 21:20:00 |
By Kim Richters
Roche Holding AG said Monday that it is voluntarily withdrawing the U.S. indication for Tecentriq in metastatic bladder cancer that previously received platinum-based therapy.
The Swiss pharmaceutical major said this was decided in consultation with the U.S. Food and Drug Administration, which was reviewing accelerated approvals across the industry.
Roche received the accelerated approval for this indication in 2016 based on results from the IMvigor210 study. It now said the study didn't meet its primary endpoint and new treatment options had emerged.
"While the withdrawal of Tecentriq for prior-platinum treated bladder cancer is disappointing, Tecentriq continues to demonstrate benefits across multiple cancer types and therefore remains a meaningful treatment option for many patients," Roche's Chief Medical Officer Levi Garraway said.
Other approved indications for the drug aren't affected, the company said.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
March 08, 2021 01:44 ET (06:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions